Tramadol inhibits proliferation, migration and invasion via α2-adrenoceptor signaling in breast cancer cells

European Review for Medical and Pharmacological Sciences

Volumn 20, Issue 1, 2016, Pages 157-165

  Xia, M ^a   Tong, J H ^a   Zhou, Z Q ^a   Duan, M L ^a   Xu, J G ^a   Zeng, H J ^a   Wang, S H ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Breast cancer cells; Tramadol; Tumorgenesis; 2 adrenoceptor

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; TRAMADOL; NARCOTIC ANALGESIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; ASSAY; BREAST CANCER; CELL MIGRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MOUSE; MTT ASSAY; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; TRANSWELL ASSAY; TUMOR INVASION; WESTERN BLOTTING; WOUND HEALING ASSAY; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CELL MOTION; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; NUDE MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANALGESICS, OPIOID; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; RECEPTORS, ADRENERGIC, ALPHA-2; SIGNAL TRANSDUCTION; TRAMADOL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84958152151     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. TAO Z, SHI A, LU C, SONG T, ZHANG Z, ZHAO J. Breast cancer: epidemiology and etiology. Cell Biochem Biophys 2014; 72: 333-338.
2. SIEGEL RL, MILLER KD, JEMAL A. Cancer statistics 2015. CA Cancer J Clin 2015; 65: 5-29.
3. HORTOBAGYI GN, DE LA GARZA SALAZAR J, PRITCHARD K, AMADORI D, HAIDINGER R, HUDIS CA, KHALED H, LIU MC, MARTIN M, NAMER M, O'SHAUGHNESSY JA, SHEN ZZ, ALBAIN KS; ABREAST Investigators. The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer 2005; 6: 391-401.
4. JONES SE. Metastatic breast cancer: the treatment challenge. Clin Breast Cancer 2008; 8: 224-233.
5. DWORKIN RH, O'CONNOR AB, BACKONJA M, FARRAR JT, FINNERUP NB, JENSEN TS, KALSO EA, LOESER JD, MIASKOWSKI C, NURMIKKO TJ, PORTENOY RK, RICE AS, STACEY BR, TREEDE RD, TURK DC, WALLACE MS. Pharmacologic management of neuropathic pain: evidence- based recommendations. Pain 2007; 132: 237-251.
6. O'CONNOR AB, DWORKIN RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med 2009; 122: S22-32.
7. GROND S, SABLOTZKI A. Clinical pharmacology of tramadol. Clin Pharmacokinet 2004; 43: 879-923.
8. FRINK MC, HENNIES HH, ENGLBERGER W, HAURAND M, WILFFERT B. Influence of tramadol on neurotransmi t ter systems of the rat brain. Arzneimi ttelforschung 1996; 46: 1029-1036.
9. SCOTT LJ, PERRY CM. Tramadol: A review of its use in perioperative pain. Drugs 2000; 60: 139-176.
10. SAKAKIYAMA M, MAEDA S, ISAMI K, ASAKURA K, SO K, SHIRAKAWA H, NAKAGAWA T, KANEKO S. Preventive and alleviative effect of tramadol on neuropathic pain in rats: roles of a-adrenoceptors and spinal astrocytes. J Pharmacol Sci 2014; 124: 244-257.
11. GACH K, WYREBSKA A, FICHNA J, JANECKA A. The role of morphine in regulation of cancer cell growth. Naunyn Schmiedebergs Arch. Pharmacol 2011; 384: 221-230.
12. LIANG H, GU MN, YANG CX, WANG HB, WEN XJ, ZHOU QL. Sevoflurane Inhibits Proliferation, Induces Apoptosis, and Blocks Cell Cycle Progression of Lung Carcinoma Cells. Asian Pac J Cancer Prev 2011; 12: 3415-3420.
13. LIANG H, GU M, YANG C, WANG H, WEN X, ZHOU Q. Sevoflurane inhibits invasion and migration of lung cancer cells by inactivating the p38 MAPK signaling pathway. J Anesth 2012; 26: 381-392.
14. XU YB, DU QH, ZHANG MY, YUN P, HE CY. Propofol suppresses proliferation, invasion and angiogenesis by down-regulating ERK-VEGF/MMP-9 signaling in Eca-109 esophageal squamous cell carcinoma cells. Eur Rev Med Pharmacol Sci 2013; 17: 2486-2494.
15. SCHULLER HM. Mechanisms of smoking-related lung and pancreatic adenocarcinoma development. Nat Rev Cancer 2002; 2: 455-463.
16. CIVANTOS CALZADA B, ALEIXANDRE DE ARTIÑANO A. Alpha- adrenoceptor subtypes. Pharmacol Res 2001; 44: 195-208.
17. WALLUKAT G. The beta-adrenergic receptors. Herz 2002; 27: 683-690.
18. VÁZQUEZ SM, MLADOVAN AG, PÉREZ C, BRUZZONE A, BALDI A, LÜTHY IA. Human breast cell lines exhibit funct ional alpha2-adrenoceptors. Cancer Chemother Pharmacol 2006; 58: 50-61.
19. BRUZZONE A, PIÑERO CP, CASTILLO LF, SARAPPA MG, ROJAS P, LANARI C, LÜTHY IA. alpha2-Adrenoceptor action on cell proliferation and mammary tumour growth in mice. Br J Pharmacol 2008; 155: 494-504.
20. BRUZZONE A, PIÑERO CP, ROJAS P, ROMANATO M, GASS H, LANARI C, LÜTHY IA. alpha2-Adrenoceptors Enhance Cell Proliferation and Mammary Tumor Growth Acting Through both the Stroma and the Tumor Cells. Curr Cancer Drug Targets 2011; 11: 763-774.
21. SHEN SG, ZHANG D, HU HT, LI JH, WANG Z, MA QY. Effects of alpha-adrenoreceptor antagonists on apoptosis and proliferation of pancreatic cancer cells in vitro. World J Gastroenterol 2008; 14: 2358-2363.
22. FARON-GÓRECKA A, KUMIDER M, INAN SY, SIWANOWICZ J, DZIEDZICKA-WASYLEWSKA M. Effects of tramadol on alpha2-adrenergic receptors in the rat brain. Brain Res 2004; 1016: 263-267.
23. RODRIGUEZ N, RODRIGUEZ PEREIRA E. Tramadol in cancer pain. Curr Ther Res 1989; 46: 1142-1148.
24. LINTZ W, ERLAÇIN S, FRANKUS E, URAGG H. Biotransformat ion of tramadol in man and animal . Arzneimittelforschung 1981; 31: 1932-1943.
25. WU C, LI H, ZHAO H, ZHANG W, CHEN Y, YUE Z, LU Q, WAN Y, TIAN X, DENG A. Potentiating antilymphoma efficacy of chemotherapy using a liposome for integration of CD20 targeting, ultra-violet irradiation polymerizing, and controlled drug delivery. Nanoscale Res Lett 2014; 9: 447.
26. KYPRIANOU N, BENNING CM. Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res 2000; 60: 4550-4555.
27. WANG L, LIU T, NISHIOKA M, AGUIRRE RL, WIN SS, OKADA N. Activation of ERK1/2 and cyclin D1 expression in oral tongue squamous cell carcinomas: Relationship between clinicopathological appearances and cell proliferation. Oral Oncol 2006; 42: 625-631.
28. LI Q, YANG Z. Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations. J Exp Clin Cancer Res 2009; 28: 65.
29. YANG Y, PARK H, YANG Y, KIM TS, BANG SI, CHO D. Enhancement of cell migration by corticotropin-releasing hormone through ERK1/2 pathway in murine melanoma cell line, B16F10. Exp Dermatol 2007; 16: 22-27.
30. CHENA Q, TIANA S, ZHUB J, LIA KT, YUC TH, YUB LH, BAI DQ. Exploring a novel target treatment on breast cancer: aloe-emodin mediated photodynamic therapy induced cell apoptosis and inhibited cell metastasis. Anticancer Agents Med Chem 2015.
31. GUO Y, ZHANG Y, YANG X, LU P, YAN X, XIAO F, ZHOU H, WEN C, SHI M, LU J, MENG QH. Effects of Methylglyoxal and Glyoxalase I Inhibition on Breast Cancer Cells Proliferation, Invasion, and Apoptosis through Modulation of MAPKs, MMP9, and Bcl-2. Cancer Biol Ther 2015.
32. LUO S, HUANG G, WANG Z, WAN Z, CHEN H, LIAO D, CHEN C, LI H, LI B, CHEN L, HUANG Z, HE Z. Niflumic acid exhibits anti-tumor activity in nasopharyngeal carcinoma cells through affecting the expression of ERK1/2 and the activity of MMP2 and MMP9. Int J Clin Exp Pathol 2015; 8: 9990-10001.